Phreesia (NYSE:PHR) Given New $34.00 Price Target at JMP Securities

Key Points

• Phreesia had its price target raised by JMP Securities from $30.00 to $34.00, indicating a potential upside of 23.20% from its current price.
• Thirteen analysts have given Phreesia a consensus rating of "Buy" with an average target price of $33.64.
• The company's recent earnings report surpassed expectations, reporting $0.01 earnings per share against an estimated loss of ($0.07).

Phreesia (NYSE:PHR - Get Free Report) had its target price lifted by investment analysts at JMP Securities from $30.00 to $34.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a "market outperform" rating on the stock. JMP Securities' target price would indicate a potential upside of 23.20% from the company's current price.

Several other equities research analysts have also commented on the company. Canaccord Genuity Group boosted their price target on Phreesia from $34.00 to $38.00 and gave the stock a "buy" rating in a research note on Friday. Raymond James Financial set a $33.00 price target on Phreesia in a research note on Friday. Mizuho assumed coverage on shares of Phreesia in a research note on Wednesday, August 27th. They set an "outperform" rating and a $36.00 price objective for the company. DA Davidson assumed coverage on shares of Phreesia in a research note on Friday. They set a "buy" rating and a $33.00 price objective for the company. Finally, Piper Sandler raised their price objective on shares of Phreesia from $33.00 to $34.00 and gave the stock an "overweight" rating in a research note on Friday. Thirteen analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $33.64.

Phreesia Stock Performance

Shares of PHR stock traded down $0.53 during trading hours on Monday, reaching $27.60. 185,338 shares of the company's stock were exchanged, compared to its average volume of 559,516. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.95 and a quick ratio of 1.95. Phreesia has a 1 year low of $17.07 and a 1 year high of $32.76. The company has a market cap of $1.64 billion, a P/E ratio of -65.86 and a beta of 0.72. The company's 50 day moving average is $28.34 and its two-hundred day moving average is $26.51.

Phreesia (NYSE:PHR - Get Free Report) last posted its quarterly earnings results on Thursday, September 4th. The company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.08. Phreesia had a negative net margin of 5.35% and a negative return on equity of 9.00%. The business had revenue of $117.26 million for the quarter, compared to analysts' expectations of $116.39 million. During the same period in the prior year, the company posted ($0.03) EPS. The business's revenue for the quarter was up 14.9% on a year-over-year basis. Phreesia has set its FY 2026 guidance at EPS. Equities research analysts anticipate that Phreesia will post -1.1 EPS for the current fiscal year.

Insider Buying and Selling at Phreesia

In related news, Director Lisa Egbuonu-Davis sold 2,802 shares of the business's stock in a transaction that occurred on Thursday, June 26th. The shares were sold at an average price of $27.67, for a total value of $77,531.34. Following the completion of the sale, the director directly owned 22,037 shares in the company, valued at approximately $609,763.79. The trade was a 11.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP David Linetsky sold 23,729 shares of the business's stock in a transaction that occurred on Friday, June 27th. The shares were sold at an average price of $28.50, for a total transaction of $676,276.50. Following the completion of the sale, the senior vice president owned 193,510 shares of the company's stock, valued at approximately $5,515,035. The trade was a 10.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 112,443 shares of company stock valued at $3,383,191. 5.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. KBC Group NV purchased a new position in shares of Phreesia in the 1st quarter worth about $74,000. Farther Finance Advisors LLC increased its position in Phreesia by 9,375.0% during the 2nd quarter. Farther Finance Advisors LLC now owns 3,032 shares of the company's stock worth $86,000 after purchasing an additional 3,000 shares in the last quarter. CWM LLC raised its holdings in Phreesia by 994.9% in the first quarter. CWM LLC now owns 4,040 shares of the company's stock valued at $103,000 after buying an additional 3,671 shares during the period. Smartleaf Asset Management LLC lifted its position in Phreesia by 53.0% during the first quarter. Smartleaf Asset Management LLC now owns 5,267 shares of the company's stock valued at $137,000 after buying an additional 1,825 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in Phreesia by 10,605.7% during the first quarter. GAMMA Investing LLC now owns 5,674 shares of the company's stock worth $145,000 after buying an additional 5,621 shares during the period. 92.10% of the stock is owned by hedge funds and other institutional investors.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.